ABP 300 - COVID-2019 infections
Alternative Names: ABP-300 - Abpro Therapeutics/Mabwell Biosciences; ABP-300 - Abpro-Therapeutics; ABP-300 - COVID-2019 infectionsLatest Information Update: 16 Oct 2023
At a glance
- Originator Abpro Therapeutics; Mabwell (Shanghai) Bioscience
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections